Pre-Dialysis Kidney Disease Market Heats Up With Oral Zemplar NDA, Hectorol Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Bone Care International's launch of the first vitamin D compound approved for secondary hyperparathyroidism in pre-dialysis patients (Hectorol) coincides with Abbott's NDA filing for Zemplar capsules.
You may also be interested in...
Genzyme Expands Renal Disease Business With $600 Mil. Acquisition Of Bone Care
Genzyme will gain Bone Care International’s sole product, Hectorol, for chronic kidney disease. The vitamin D therapy is often used concomitantly with Genzyme’s phosphate binder Renagel. Sales force cuts are expected upon the completion of the merger.
Genzyme Expands Renal Disease Business With $600 Mil. Acquisition Of Bone Care
Genzyme will gain Bone Care International’s sole product, Hectorol, for chronic kidney disease. The vitamin D therapy is often used concomitantly with Genzyme’s phosphate binder Renagel. Sales force cuts are expected upon the completion of the merger.
Hectorol Label Hectored by ISMP
Medical safety organization says FDA will "look into" labeling of Bone Care International's Hectorol, which includes a mu and trailing zero.